X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, GSK has selected its first two programs to advance to development candidates following achievement of target validation. These programs utilize Wave’s next generation GalNAc-siRNA format and are in hepatology.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $3,312.0 million Upfront Cash: $12.0 million
Deal Type: Collaboration April 23, 2024
Details:
WVE-N531 is an investigational stereopure antisense oligonucleotide being developed as a potential therapy for patients with duchenne muscular dystrophy (DMD) amenable to exon 53 skipping..
Lead Product(s): WVE-N531
Therapeutic Area: Genetic Disease Product Name: WVE-N531
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
The net proceeds from this offering will be used to advance RNA editing pipeline of programs, including WVE-006 and to accelerate the development of Wave's INHBE program into the clinical.
Lead Product(s): WVE-006
Therapeutic Area: Genetic Disease Product Name: WVE-006
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 07, 2023
Details:
The net proceeds from the offering will be used to advance RNA editing pipeline of programs, including WVE-006 and to accelerate the development of Wave's INHBE program into the clinical.
Lead Product(s): WVE-006
Therapeutic Area: Genetic Disease Product Name: WVE-006
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 06, 2023
Details:
WVE-006 is a clinical-stage GalNAc-conjugated investigational RNA editing oligonucleotide being developed for the treatment of alpha-1 antitrypsin deficiency (AATD).
Lead Product(s): WVE-006
Therapeutic Area: Genetic Disease Product Name: WVE-006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
WVE-006 is a clinical-stage GalNAc-conjugated investigational RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency (AATD).
Lead Product(s): WVE-006
Therapeutic Area: Genetic Disease Product Name: WVE-006
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
WVE-004 is an ASO designed with Wave’s proprietary and best-in-class chemistry, which selectively targets transcriptional variants containing the hexanucleotide repeat expansion (G4C2) associated with the C9orf72 gene, thereby sparing normal C9orf72 protein.
Lead Product(s): WVE-004
Therapeutic Area: Neurology Product Name: WVE-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
High muscle concentrations of WVE-N531 and exon skipping were observed six weeks after initiating biweekly multidosing at 10 mg/kg, achieving proof-of-concept in the study. WVE-N531 also appeared safe and well-tolerated.
Lead Product(s): WVE-N531
Therapeutic Area: Genetic Disease Product Name: WVE-N531
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
The collaboration includes 2 components, first is a discovery collaboration which enables GSK to advance upto 8 programmes and Wave upto 3 programmes, using Wave’s PRISM platform in genetics and genomics. GSK will in-license Wave’s preclinical programme WVE-006 for AATD.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $3,335.0 million Upfront Cash: $170.0 million
Deal Type: Collaboration December 13, 2022
Details:
WVE-004 is stereopure antisense oligonucleotide designed to selectively target transcriptional variants containing a hexanucleotide repeat expansion associated with C9orf72 gene, thereby sparing C9orf72 protein.
Lead Product(s): WVE-004
Therapeutic Area: Neurology Product Name: WVE-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
